DE-BIOCORP
19.2.2020 18:02:08 CET | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization.
In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management.
This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration").
Ryan Sysko, President and CEO of Amalgam Rx, Inc, said: "We are very pleased with this partnership to interface Mallya with our iSage app. Combining these two solutions offers to date the most powerful environment for diabetes digitalization and patient support. Together, we can simplify the often complex and confusing journey for patients starting on basal insulin. “
Éric Dessertenne, CEO of BIOCORP, concluded: "For patients with diabetes, the integration of Mallya and iSage provides an additional brick of information to improve their quality of life. For the community of diabetes, this integration is a powerful service platform that takes into account all the clinical and behavioral needs of patients. "
ABOUT ISAGE RX
iSage Rx, manufacturers of the iSage App, the first FDA 510(k)-cleared, prescription-only mobile application for the automated titration of all brands of basal insulin. iSage allows physicians to choose from multiple clinically-validated basal insulin algorithms and tailor the algorithms to the specific needs of their type 2 diabetes patients. iSage Rx is a wholly-owned subsidiary of Amalgam Rx. For more information, visit http://isageapp.com .
ABOUT AMALGAM RX
Amalgam Rx creates custom digital therapies that combine clinical and behavioral health and interventions to engage, support, and improve patient self-management. Led by an experienced team of physicians, behaviorists, technologists, and digital health pioneers, Amalgam Rx strives to use technology to accelerate the impact and scale of medicine to improve the lives of millions of people living with chronic disease. Amalgam does this by partnering with leading life sciences companies to accelerate the R&D and commercialization of digital therapeutics. For more information, visit http://amalgamrx.com/ .
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
Follow us on Twitter @BIOCORPSystems
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219005728/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
K2 Partnering Solutions Appoints Srinivas Rao as Chief Executive Officer16.2.2026 10:00:00 CET | Press release
K2 Partnering Solutions, a global leader in consultative technology and talent solutions, today announced the appointment of Srinivas Rao as Chief Executive Officer. Srinivas is a seasoned global executive with more than 28 years of experience driving value creation, scalable growth, and operational transformation across digital, consulting, IT services, and business services. He brings deep expertise in leading complex, multi-market organisations and has successfully scaled $800M+ P&Ls, working closely with boards, sponsors, and executive leadership teams across the USA, UK, Europe, the Middle East, and APAC. Most recently, Srinivas served as Chief Business Officer and a member of the Executive Council at LTIMindtree, where he was accountable for growth acceleration, market expansion, strategic customer relationships, and operating performance across a highly complex regional footprint. During his tenure, he played a pivotal role in strengthening go-to-market execution, driving margin
Italy Sees Economic Boost From the Opening Weekend of the Olympic Winter Games Milano Cortina 202616.2.2026 09:00:00 CET | Press release
Northern Italy sees more than 60% increase in Visa cardholder visitors from overseas, with an increase in purchases up 80% compared to the same period in 2025 Significant increase in spending from Visa cardholders in many areas of commerce including Clothing & Accessories, Restaurants and Mobility & Transport Biggest share of spend comes from U.S. Visa cardholders, with most significant increases in year-on-year spending from Canada and Switzerland Visa, the Official Payment Technology Partner of the Olympic and Paralympic Winter Games, today released new data revealing consumer spending patterns in the Winter Games host locations1 during the opening weekend of the Olympic Winter Games Milano Cortina 2026. VisaNet data analysed by Visa Consulting & Analytics (VCA) shows the positive impact that Milano Cortina 2026 is having on commerce: Overseas Visa cardholders visits rose by more than 60%, with the largest share of visitors coming from the U.S. (+160% year-on-year), followed by China
Klarna Launches on Google Pay in the UK16.2.2026 09:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, is now available on Google Pay in the UK. Google Pay users in the U.K. can choose Klarna’s interest-free payment options at checkout. Raji Behal, Head of Western and Southern Europe, UK & Ireland at Klarna, said, “We’re really excited to bring Klarna’s fair, flexible and interest-free payment options to Google Pay users. This is a big moment for us and a major step towards our goal of being available at every checkout, everywhere. Together with Google, we’re making it easier than ever for millions of shoppers to choose Klarna and pay in a smarter, more transparent way — all from their phone.” Lisa Yokoyama, Director of Product Management at Google Paysaid: "Expanding our collaboration with Klarna to the U.K. underscores our goal to empower more people with the flexibility to pay how they choose. With people shopping on Google over a billion times a day, this broader footprint provides even more checkout options to help bus
New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday16.2.2026 08:00:00 CET | Press release
A new post-hoc analysis from the LIBERTY studies, presented at ECCO 2026, demonstrated that initiating subcutaneous (SC) infliximab (Remsima™ SC) after a treatment interruption following intravenous (IV) infliximab induction helps patients with Crohn’s disease (CD) and ulcerative colitis (UC) recapture and maintain disease control1The results demonstrated that SC infliximab provides an effective and safe option to regain clinical control after a planned or unplanned treatment interruptionMore than a total of 30 accepted abstracts including one oral and one digital oral presentation and eight posters, reinforce Celltrion’s commitment to inflammatory bowel disease (IBD) research aimed at enhancing patient outcomes Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustai
Galderma Announces Appointment of New Chief Financial Officer16.2.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026. Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization. “Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom